Hybrid blood purification combined with chemotherapy in the treatment of hemophagocytic lymphohistiocytosisn in children

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022592

Enrollment

Unknown

Registered

2019-04-17

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemophagocytic lymphohistiocytosisn

Interventions

Case series:hybrid blood purification combined with chemotherapy

Eligibility

Sex/Gender

All

Age

No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1. Fever persisted 48 hours after chemotherapy, progressive decrease of trilineage and continuous increase of SF; 2. those with complications at the time of diagnosis; 3. Recurrence after remission, and those with the above conditions.

Exclusion criteria

Exclusion criteria: Those who used glucocorticoids or immunosuppressive agents within 72 hours before admission.

Design outcomes

Primary

Measure	Time frame
ferritin;neutrophil;hemoglobin;thrombocyte;glutamic-pyruvic transaminase;NK activity;Fibrinogen;triglyceride;Hemophagocytosis;Total bilirubin;	—

Countries

China

Contacts

Public ContactChenYan

Affiliated Hospital of Zunyi Medical College

cyz600@163.com+86 13985261758

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026